Biotage AB (Biotage AB) Cash-to-Debt

: 2.29 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biotage AB's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.29.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Biotage AB could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Biotage AB's Cash-to-Debt or its related term are showing as below:

BITGF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.78 Med: 2.29 Max: 265.65
Current: 2.29

During the past 13 years, Biotage AB's highest Cash to Debt Ratio was 265.65. The lowest was 0.78. And the median was 2.29.

BITGF's Cash-to-Debt is ranked better than
51.8% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 2.01 vs BITGF: 2.29

Biotage AB Cash-to-Debt Historical Data

The historical data trend for Biotage AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biotage AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.78

2.29

1.53

2.03

2.29

Biotage AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																2.03	1.95	1.19	1.23	2.29

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Biotage AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotage AB Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biotage AB's Cash-to-Debt falls into.

Biotage AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biotage AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	57.908	/	(3.217	+	22.032)
	=	2.29

Biotage AB's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	57.908	/	(3.217	+	22.032)
	=	2.29

Biotage AB (OTCPK:BITGF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biotage AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biotage AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotage AB (Biotage AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OTCPK:BITGF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BIOT:Sweden 0GRP:UK PQX1:Germany

Address

Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03

Website

https://www.biotage.com

Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.